Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Q&A: Marion Munk on IntRIS symposium at EURETINA 2025

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

Researchers propose new explanation for drusen regression without atrophy

Videos

We ask leading experts in the field what eye disease they would cure and why.

Part 3: What if? Curing any eye disease with the snap of your finger

Q&A: Giuseppe Querques on PVAC and TelCaps

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

1rem

Thanks for your interest in this podcast. Please read this important program information before listening.

In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive strategies when performing corneal sensitivity testing in patients suspected of having neurotrophic keratitis (NK).

Upon successful completion of this activity, you should be better prepared to:

Summarize the importance of a timely and accurate diagnosis of neurotrophic keratitis

Integrate corneal sensitivity testing into the assessment of ocular surface disease

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Dompé US, Inc; and Brill Engines.

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA

Director, Specialty Contact Lens Division
Cornea and Laser Eye Institute
CLEI Center for Keratoconus
Assistant Clinical Professor, Department of Ophthalmology
Rutgers New Jersey Medical School
Adjunct Clinical Professor, New England College of Optometry
State University of New York College of Optometry
Illinois College of Optometry
Teaneck, NJ

President, Harvard Eye Associates
Specialist in Cornea, External Ocular Disease, Refractive and Cataract Surgery
Clinical Faculty, UCLA Jules Stein Eye Institute
Laguna Hills, CA

AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord LLC, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight LLC, Sight Sciences, Sun Pharma, Zeiss;

AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight LLC, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Ophthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; 

Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight LLC, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the latest treatment strategies for patients with neurotrophic keratitis, go to 

https://www.gotoper.com/courses/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

Glaucoma is a leading cause of irreversible blindness and affects approximately 80 million people globally, with projections to exceed 111 million by 2040. We know that the elevated intraocular pressure is the key modifiable risk factor which is why reducing intraocular pressure is central to treatment strategies.

In this podcast, expert faculty from the featured symposium at the 2025 EnVision Summit share insights about interventional glaucoma co-management.

 from Moran Eye Center in Salt Lake City, UT; 

 from Connecticut Eye Physicians in New Haven, CT; 

 from the Cleveland Clinic’s Cole Eye Institute in Cleveland, Ohio; and optometrist Jessica Steen from the Nova Southeastern University College of Optometry in Fort Lauderdale, FL.

This activity is supported by educational grants from Alcon and Sun Pharmaceutical Industries, Inc.

Glaucoma Specialist
Residency Program Director
Vice Chair of Education
Moran Eye Center
Salt Lake City, UT

 AbbVie, Elios Vision, Glaukos, Nova Eye Medical; 

Consulting Surgeon
Scarsdale Ophthalmology Associates
Keyhani Eye Associates
Jefferson Valley, NY
Connecticut Eye Physicians
New York and Connecticut
New Haven, CT

; MST, Nextech, Nova Eye Medical, Sight Sciences: 

: Bausch + Lomb, Glaukos, MST, Nova Eye Medical, Sight Sciences, RxSight; 

Associate Program Director
Cole Eye Institute
Cleveland Clinic
Cleveland, OH

Associate Professor
Director, Glaucoma Service
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

: Alcon, Allergan, Astellas Pharma, Bausch + Lomb, Carl Zeiss Meditec, Viatris; 

: Alcon, Allergan, Astellas Pharma, Bausch + Lomb, Carl Zeiss Meditec, Eyenovia, Glaukos, iCare, Ocuphire Pharma, OcuTerra Therapeutics, Opus Genetics, Peripherex, RadiusXR, Santen Pharmaceutical, Viatris; 

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

3 Things You Should Know About Interventional Glaucoma Comanagement

Recently approved anti-VEGF agents that target additional pathways and offer innovative delivery methods with longer-lasting effects may provide advantages over older anti-VEGF agents in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this podcast, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD and DME in an evolving treatment landscape, from screening and diagnosis to referral and ongoing patient care.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Frederick M. Leader Professor of Ophthalmology
Associate Professor of Ophthalmology, Retina Division
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD

: Apellis, EyePoint, Genentech/Roche, Iveric Bio, Regeneron; 

Assistant Professor
Department of Ophthalmology and Vision Sciences
University of Illinois College of Medicine
Chicago, IL

Justine Cheng, MD, has no relevant financial relationships with ineligible companies.

Assistant Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL

 AbbVie, Alcon, Alimera Sciences/ANI Pharmaceuticals, Genentech.

Professor of Optometry
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

 American Diabetes Association, Genentech, Regeneron, Vision Service Plan (VSP).

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Thyroid eye disease (TED), a rare autoimmune condition, can be sight-threatening, debilitating, and disfiguring, severely impacting patients’ quality of life and daily functioning. Traditional management approaches for TED have centered on immunomodulatory therapy and surgical interventions. In January 2020, the US Food and Drug Administration (FDA) approved teprotumumab, the first therapy specifically indicated for TED. As treatment options evolve, there is an increasing need for a patient-centered, multidisciplinary approach, which is essential to address individual patient needs throughout the disease course.

 podcast provides an in-depth review of some of the key highlights from a satellite symposium that took place at the Envision Summit 2025 meeting in February 2025.This unique and engaging activity focuses on the practical aspects of managing patients with thyroid eye disease, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

This activity is supported by an educational grant from Amgen, Inc.

Professor of Clinical Ophthalmology
Oculofacial Plastic and Reconstructive Surgery
Orbital Surgery and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

 Amgen, Argenx, Horizon Therapeutics, Immunovant, Tourmaline Bio; 

Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Anschutz Medical Campus
Denver, CO

 Alcon, Aldeyra Therapeutics, Allergan/AbbVie, Avellino, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder, Claris Bio, Dompé, Eyevance/Santen Pharmaceutical, Glaukos, KALA BIO, Myze, Orasis Pharmaceuticals, Oyster Point Pharma/Viatris, RVL Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Thea, Topcon, Twenty/Twenty Therapeutics, Verséa, Visus Therapeutics

Robert H. Bell Endowed Chair in Ophthalmology
Associate Chief Medical Officer of Ambulatory Services
UCHealth University of Colorado Hospital
Associate Professor, Division of Oculofacial Plastic and Reconstructive Surgery
Department of Ophthalmology
University of Colorado School of Medicine
Aurora, CO

Dr Liao has no relevant financial relationships with ineligible companies to disclose.

CEO/Owner
Jennifer Murdock, MD, PLLC
Miami, FL

3 Things You Should Know About Early Treatment Intervention for TED

Geographic atrophy, an advanced stage of age-related macular degeneration, is a significant cause of vision loss. Given the progressive nature of geographic atrophy and its significant impact on quality of life, educating health care professionals about the disease burden, diagnostic strategies, and evolving management strategies is essential.

 podcast provides an in-depth review of some of the key highlights from the Envision Summit 2025 meeting, held in February 2025. This unique and engaging activity focuses on the practical aspects of managing patients with geographic atrophy, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

This activity is supported by educational grants from Astellas Pharma US, Apellis Pharmaceuticals, Carl Zeiss Meditec.

Assistant Professor of Ophthalmology and Visual Science
Assistant Professor of Pathology
UChicago Medicine
Chicago, IL

Xiao Yi (Ellie) Zhou, MD, has no relevant financial relationships with ineligible companies to disclose.

3 Things You Should Know About the GA Pipeline 

The lacrimal functional unit, which includes the lacrimal glands and meibomian glands, can be stimulated via the trigeminal nerve to trigger production of the tear film. This approach can be used to manage dry eye disease (DED) in patients undergoing corneal refractive surgery. In this podcast, an expert explores opportunities to use this approach to treat patients with DED.

This activity is supported by educational grants from Viatris, Inc, and Nordic Pharma, Inc.

Associate Professor of Ophthalmology
Cornea Fellowship Director
Willis Eye Hospital
Philadelphia, PA

 BioTissue, Bruder, Glaukos, Recordati Rare Diseases; 

 BioTissue, Recordati Rare Diseases, Tarsus; 

The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-friendly, multispecialty CME ophthalmology conference, along with a newly introduced optometry track. Henderson sits down with 

' Sheryl Stevenson, group editorial director - eye care, to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Henderson describes the meeting as “a place where not only are physicians and optometrists learning, but their families are part of the experience too,” emphasizing the opportunity for personal and professional growth in a supportive, community-oriented environment.

The 2025 agenda will include symposia, surgical videos, panel discussions, and leadership seminars that highlight rapid advancements across ophthalmology specialties, including cataract, refractive, retina, glaucoma, pediatrics, and oculoplastics. “It’s incredible how quickly things change in ophthalmology—if you miss a year or two, you’ll be amazed by the innovations that have emerged,” Henderson shared. Updates on new intraocular lenses, surgical tools, and diagnostic techniques will showcase the field’s forward momentum. Additionally, a leadership seminar led by Malvina Eydelman, MD, Director of the Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices at FDA, Silver Spring, Maryland, will feature discussions on career pathways and diversity, empowering attendees with insights from industry leaders.

The optometry track, introduced last year, continues to expand, emphasizing collaboration between ophthalmologists and optometrists in critical areas like preoperative and postoperative care, medications, and diagnostic tools. As Henderson explained, “It's important for both fields to come together and discuss how we can work together to improve patient care.” This cross-disciplinary dialogue reflects the summit's dedication to advancing care through shared expertise.

The youth program offers age-appropriate activities that allow children to engage in fun learning while also witnessing their parents' professional contributions. "It’s amazing to watch these kids grow up at EnVision Summit and form lasting friendships,” said Henderson. The trainee program, which offers free registration for residents, fellows, and medical students, has also seen growth. Henderson highlighted the program’s value, noting that it “gives young professionals the chance to network with leaders in the field and gain invaluable mentorship.”



To learn more about or to register for EnVision Summit 2025,

EnVision Summit

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Connect, learn, and innovate in a family-friendly atmosphere:  What to expect at EnVision Summit 2025

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias. 

Green outlines the status of the research, involving a unique combination of transforming growth factor beta-3 and dexamethasone, and the setup for a proof-of-concept study (via TheiaNova, a spin-out early-stage company of the University of Auckland). 

Green also offers career advice for vision scientists and entrepreneurs, advising that making the transition from basic research to research translation is challenging and that having an application in mind is crucial. He emphasizes the importance of persevering through the highs and lows of research and development, highlighting the long-term benefits and sense of achievement.

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias. 

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Thyroid eye disease is a condition frequently associated with Graves disease that involves both acute and chronic inflammation of the orbit. Patients may experience ocular discomfort, appearance changes, and vision loss. In this podcast, an expert panel discusses diagnosing TED and providing appropriate pharmacologic and surgical treatments. 

In this PER On Air Ophthalmology Times podcast, an expert panel discusses diagnosing TED and providing appropriate pharmacologic and surgical treatments. 

Advancing the optimal diagnosis & treatment of thyroid eye disease

 podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK.

Clinical Assistant Professor of Ophthalmology

Vice President, Board of Trustees of Virginia Optometric

Secretary/Treasurer, Richmond Optometric Society

Assistant Professor, Uniformed Services University, School of Medicine, Physical Medicine and Rehabilitation Department

Assistant Professor of Clinical Ophthalmology

Pediatric and Adult Cornea, Cataract, and External Diseases

Director of Ophthalmology Medical Student Education

Bascom Palmer Eye Institute, University of Miami Miller School of Medicine

In this PER On Air Ophthalmology Times podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK. 

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

From firsts to the future: A pioneer's perspective on ophthalmology

Robotic laser arcuate incisions reduce variability and residual astigmatism.

Dialing in precision: Astigmatism management with arcuate incisions

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan

The primary end point of the trial was complete resolution of debris after 6 weeks of twice-daily dosing.

Cornea

Latest News